Semaphorins are membrane-bound or diffusible factors that regulate key cellular functions and are involved in cell–cell communication. Most of the effects of semaphorins are mediated by plexins.
Work over the past decade has revealed crucial functions of the semaphorin–plexin system in mammalian physiology. It has also become clear that semaphorins and plexins have important roles in many pathophysiological processes and that they represent novel targets for drugs to prevent or treat various diseases.
Several semaphorins and plexins are critically involved in tumour growth and metastasis by controlling tumour development and progression via the formation of autocrine signalling loops in cancer cells, as well as by regulating the interaction of different cells within the tumour.
Semaphorins and plexins have also been found to control immune functions by regulating immune cell activation, differentiation and trafficking, and several semaphorins and plexins have crucial roles in inflammatory and autoimmune diseases.
Semaphorin 3A and semaphorin 4D have important roles in promoting bone formation and resorption, respectively, and semaphorin 3A and inhibitors of semaphorin-4D-induced signalling have been suggested as potential agents to prevent bone loss.
Semaphorin 3A and semaphorin 3E appear to promote particular diseases of the microvasculature, and therapies that target these semaphorins and their downstream signalling events may be promising approaches to treat microvascular diseases.
Notably, semaphorin 3A has been suggested to be a critical factor that impedes the regeneration of the central nervous system, and several experimental drugs have been developed to inhibit semaphorin 3A activity in order to promote central nervous system regeneration.
Several semaphorins and plexins have been identified as potential targets for drugs to treat particular diseases, such as cancer, immunological disorders, osteoporosis or microvascular diseases. The development of specific ligands or inhibitors is ongoing; indeed, antibodies that are directed against semaphorin 4D are currently being tested in clinical trials.
Semaphorins are membrane-bound or diffusible factors that regulate key cellular functions and are involved in cell–cell communication. Most of the effects of semaphorins are mediated by plexins. Work over the past decade has revealed crucial functions of the semaphorin–plexin system in mammalian physiology. It has also become clear that semaphorins and plexins have important roles in many pathophysiological processes, including cancer, immunological diseases and bone disorders, and that they represent novel targets for drugs to prevent or treat various diseases. This Review summarizes the functions of the mammalian semaphorin–plexin system as well as its role in diseases and discusses emerging strategies to pharmacologically target semaphorin–plexin signalling.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Semaphorin Nomenclature Committee. Letter to the editor: Unified nomenclature for the semaphorins/collapsins. Cell 97, 551–552 (1999).
Potiron, V., Nasarre, P., Roche, J., Healy, C. & Boumsell, L. Semaphorin signaling in the immune system. Adv. Exp. Med. Biol. 600, 132–144 (2007).
Tamagnone, L. et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99, 71–80 (1999).
Pasterkamp, R. J. Getting neural circuits into shape with semaphorins. Nature Rev. Neurosci. 13, 605–618 (2012).
Gu, C. & Giraudo, E. The role of semaphorins and their receptors in vascular development and cancer. Exp. Cell Res. 319, 1306–1316 (2013).
Neufeld, G., Sabag, A. D., Rabinovicz, N. & Kessler, O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb. Perspect. Med. 2, a006718 (2012).
Kumanogoh, A. & Kikutani, H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nature Rev. Immunol. 13, 802–812 (2013).
Capparuccia, L. & Tamagnone, L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment—two sides of a coin. J. Cell Sci. 122, 1723–1736 (2009).
Tamagnone, L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell 22, 145–152 (2012).
Kang, S. & Kumanogoh, A. Semaphorins in bone development, homeostasis, and disease. Semin. Cell Dev. Biol. 24, 163–171 (2013).
Negishi-Koga, T. & Takayanagi, H. Bone cell communication factors and Semaphorins. BoneKEy Rep. 1, 183 (2012).
Pasterkamp, R. J. & Giger, R. J. Semaphorin function in neural plasticity and disease. Curr. Opin. Neurobiol. 19, 263–274 (2009).
Sakurai, A., Doci, C. L. & Gutkind, J. S. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Res. 22, 23–32 (2012).
Takamatsu, H. & Kumanogoh, A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol. 33, 127–135 (2012).
Roney, K., Holl, E. & Ting, J. Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell 4, 17–26 (2013).
Siebold, C. & Jones, E. Y. Structural insights into semaphorins and their receptors. Semin. Cell Dev. Biol. 24, 139–145 (2013).
Hota, P. K. & Buck, M. Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell. Mol. Life Sci. 69, 3765–3805 (2012).
Liu, H. et al. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell 142, 749–761 (2010).
Nogi, T. et al. Structural basis for semaphorin signalling through the plexin receptor. Nature 467, 1123–1127 (2010).
Janssen, B. J. et al. Structural basis of semaphorin-plexin signalling. Nature 467, 1118–1122 (2010).
Perala, N., Sariola, H. & Immonen, T. More than nervous: the emerging roles of plexins. Differentiation 83, 77–91 (2012).
Goshima, Y., Sasaki, Y., Yamashita, N. & Nakamura, F. Class 3 semaphorins as a therapeutic target. Expert Opin. Ther. Targets 16, 933–944 (2012).
Nkyimbeng-Takwi, E. & Chapoval, S. P. Biology and function of neuroimmune semaphorins 4A and 4D. Immunol. Res. 50, 10–21 (2011).
Gherardi, E., Love, C. A., Esnouf, R. M. & Jones, E. Y. The sema domain. Curr. Opin. Struct. Biol. 14, 669–678 (2004).
Klostermann, A., Lohrum, M., Adams, R. H. & Puschel, A. W. The chemorepulsive activity of the axonal guidance signal semaphorin D requires dimerization. J. Biol. Chem. 273, 7326–7331 (1998).
Koppel, A. M. & Raper, J. A. Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity. J. Biol. Chem. 273, 15708–15713 (1998).
Love, C. A. et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nature Struct. Biol. 10, 843–848 (2003).
Granja, T. et al. Crucial role of Plexin C1 for pulmonary inflammation and survival during lung injury. Mucosal Immunol. http://dx.doi.org/10.1038/mi.2013.104 (2013).
Zhou, Y., Gunput, R. A. & Pasterkamp, R. J. Semaphorin signaling: progress made and promises ahead. Trends Biochem. Sci. 33, 161–170 (2008).
Tran, T. S., Kolodkin, A. L. & Bharadwaj, R. Semaphorin regulation of cellular morphology. Annu. Rev. Cell Dev. Biol. 23, 263–292 (2007).
Janssen, B. J. et al. Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex. Nature Struct. Mol. Biol. 19, 1293–1299 (2012).
Castellani, V., De Angelis, E., Kenwrick, S. & Rougon, G. Cis and trans interactions of L1 with neuropilin-1 control axonal responses to semaphorin 3A. EMBO J. 21, 6348–6357 (2002).
Swiercz, J. M., Kuner, R. & Offermanns, S. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J. Cell Biol. 165, 869–880 (2004).
Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720–724 (2002).
Casazza, A. et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J. Clin. Invest. 120, 2684–2698 (2010).
Pasterkamp, R. J., Peschon, J. J., Spriggs, M. K. & Kolodkin, A. L. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 424, 398–405 (2003).
Suzuki, K., Kumanogoh, A. & Kikutani, H. Semaphorins and their receptors in immune cell interactions. Nature Immunol. 9, 17–23 (2008).
Oinuma, I., Ishikawa, Y., Katoh, H. & Negishi, M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 305, 862–865 (2004).
Saito, Y., Oinuma, I., Fujimoto, S. & Negishi, M. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. EMBO Rep. 10, 614–621 (2009).
Wang, Y. et al. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci. Signal. 5, ra6 (2012).
Gloerich, M. & Bos, J. L. Regulating Rap small G-proteins in time and space. Trends Cell Biol. 21, 615–623 (2011).
Swiercz, J. M., Kuner, R., Behrens, J. & Offermanns, S. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35, 51–63 (2002).
Hirotani, M. et al. Interaction of plexin-B1 with PDZ domain-containing Rho guanine nucleotide exchange factors. Biochem. Biophys. Res. Commun. 297, 32–37 (2002).
Aurandt, J., Vikis, H. G., Gutkind, J. S., Ahn, N. & Guan, K. L. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc. Natl Acad. Sci. USA 99, 12085–12090 (2002).
Perrot, V., Vazquez-Prado, J. & Gutkind, J. S. Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J. Biol. Chem. 277, 43115–43120 (2002).
Swiercz, J. M., Worzfeld, T. & Offermanns, S. Semaphorin 4D signaling requires the recruitment of phospholipase Cγ into the plexin-B1 receptor complex. Mol. Cell. Biol. 29, 6321–6334 (2009).
Tong, Y. et al. Structure and function of the intracellular region of the plexin-B1 transmembrane receptor. J. Biol. Chem. 284, 35962–35972 (2009).
He, H., Yang, T., Terman, J. R. & Zhang, X. Crystal structure of the plexin A3 intracellular region reveals an autoinhibited conformation through active site sequestration. Proc. Natl Acad. Sci. USA 106, 15610–15615 (2009).
Wang, Y., Pascoe, H. G., Brautigam, C. A., He, H. & Zhang, X. Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin. eLife 2, e01279 (2013).
Serini, G., Bussolino, F., Maione, F. & Giraudo, E. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J. Intern. Med. 273, 138–155 (2013).
Luchino, J. et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell 24, 673–685 (2013).
Tseng, C. H. et al. Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS ONE 6, e19396 (2011).
Roodink, I., Verrijp, K., Raats, J. & Leenders, W. P. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 9, 297 (2009).
Christensen, C. et al. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res. 65, 6167–6177 (2005).
Casazza, A. et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol. Med. 4, 234–250 (2012).
Sakurai, A. et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol. Cell. Biol. 30, 3086–3098 (2010).
Kigel, B., Varshavsky, A., Kessler, O. & Neufeld, G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS ONE 3, e3287 (2008).
Sabag, A. D. et al. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS ONE 7, e42912 (2012).
Roodink, I. et al. Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. Am. J. Pathol. 173, 1873–1881 (2008).
Serini, G. et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 391–397 (2003).
Maione, F. et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 119, 3356–3372 (2009).
Chakraborty, G., Kumar, S., Mishra, R., Patil, T. V. & Kundu, G. C. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS ONE 7, e33633 (2012).
Maione, F. et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 122, 1832–1848 (2012).
Casazza, A. et al. Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler. Thromb. Vasc. Biol. 31, 741–749 (2011).
Acevedo, L. M., Barillas, S., Weis, S. M., Gothert, J. R. & Cheresh, D. A. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111, 2674–2680 (2008).
Cerani, A. et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell. Metab. 18, 505–518 (2013).
Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695–709 (2013).
Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167–170 (2009).
Bielenberg, D. R. et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Invest. 114, 1260–1271 (2004).
Kessler, O. et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 64, 1008–1015 (2004).
Kusy, S. et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 7, 457–465 (2005).
Wu, F. et al. Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma. Clin. Cancer Res. 17, 2702–2711 (2011).
Xiang, R. et al. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res. 62, 2637–2643 (2002).
Wong, H. K. et al. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 14, 84–94 (2012).
Basile, J. R., Castilho, R. M., Williams, V. P. & Gutkind, J. S. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc. Natl Acad. Sci. USA 103, 9017–9022 (2006).
Sun, Q., Zhou, H., Binmadi, N. O. & Basile, J. R. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J. Biol. Chem. 284, 32066–32074 (2009).
Zhou, H., Binmadi, N. O., Yang, Y. H., Proia, P. & Basile, J. R. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 15, 391–407 (2012).
Zhou, H., Yang, Y. H., Binmadi, N. O., Proia, P. & Basile, J. R. The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp. Cell Res. 318, 1685–1698 (2012).
Sierra, J. R. et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 205, 1673–1685 (2008).
Segarra, M. et al. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 120, 4104–4115 (2012).
Sadanandam, A., Rosenbaugh, E. G., Singh, S., Varney, M. & Singh, R. K. Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc. Res. 79, 1–9 (2010).
Sadanandam, A. et al. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br. J. Cancer 107, 501–507 (2012).
Fazzari, P. et al. Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev. Biol. 7, 55 (2007).
Worzfeld, T. et al. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. J. Clin. Invest. 122, 1296–1305 (2012).
Ye, S. et al. Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer 10, 611 (2010).
Argast, G. M. et al. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene 28, 2697–2709 (2009).
Rody, A. et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin. Cancer Res. 13, 1115–1122 (2007).
Swiercz, J. M., Worzfeld, T. & Offermanns, S. ErbB-2 and Met reciprocally regulate cellular signaling via plexin-B1. J. Biol. Chem. 283, 1893–1901 (2008).
Cagnoni, G. & Tamagnone, L. Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression. Oncogene http://dx.doi.org/10.1038/onc.2013.474 (2013).
Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nature Med. 17, 1473–1480 (2011).
Okuno, T. et al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 184, 1499–1506 (2010).
Fisher, T. E., Smith, E. S. & Zauderer, M. Anti-Sema4D antibodies and epitopes. World Patent WO2013148854 (A1) (2013).
Evans, E. E. et al. Reduction of tumor growth and metastasis by a humanized IgG4 monoclonal antibody to SEMA4D (VX15/2503). Cancer Res. Abstr. 73, (Suppl. 1) 1245 (2013).
Hu, G. & Yu, W. Modulators of Plexin B2 activity. World Patent WO2012135332 (A1) (2012).
Suzuki, K. et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin. Nature 446, 680–684 (2007).
Kikutani, H. & Kumanogoh, A. Semaphorins in interactions between T cells and antigen-presenting cells. Nature Rev. Immunol. 3, 159–167 (2003).
Kumanogoh, A. et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J. Immunol. 169, 1175–1181 (2002).
Kumanogoh, A. et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 13, 621–631 (2000).
Kumanogoh, A. et al. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. Immunity 22, 305–316 (2005).
Kumanogoh, A. et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419, 629–633 (2002).
Makino, N. et al. Involvement of Sema4A in the progression of experimental autoimmune myocarditis. FEBS Lett. 582, 3935–3940 (2008).
Nakatsuji, Y. et al. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J. Immunol. 188, 4858–4865 (2012).
Nylander, A. & Hafler, D. A. Multiple sclerosis. J. Clin. Invest. 122, 1180–1188 (2012).
Nkyimbeng-Takwi, E. H. et al. Neuroimmune semaphorin 4A downregulates the severity of allergic response. Mucosal Immunol. 5, 409–419 (2012).
Morihana, T. et al. An inhibitory role for Sema4A in antigen-specific allergic asthma. J. Clin. Immunol. 33, 200–209 (2013).
Mogie, G. et al. Neuroimmune semaphorin 4A as a drug and drug target for asthma. Int. Immunopharmacol. 17, 568–575 (2013).
Rennert, P. D. et al. T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune responses and airway inflammation. J. Immunol. 177, 4311–4321 (2006).
Rice, D. S. et al. Severe retinal degeneration associated with disruption of semaphorin 4A. Invest. Ophthalmol. Vis. Sci. 45, 2767–2777 (2004).
Toyofuku, T. et al. Endosomal sorting by Semaphorin 4A in retinal pigment epithelium supports photoreceptor survival. Genes Dev. 26, 816–829 (2012).
Tsuruma, K. et al. SEMA4A mutations lead to susceptibility to light irradiation, oxidative stress, and ER stress in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 53, 6729–6737 (2012).
Nojima, S. et al. A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. Nature Commun. 4, 1406 (2013).
Takegahara, N. et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nature Cell Biol. 8, 615–622 (2006).
Bakker, A. B. et al. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13, 345–353 (2000).
O'Connor, B. P. et al. Semaphorin 6D regulates the late phase of CD4+ T cell primary immune responses. Proc. Natl Acad. Sci. USA 105, 13015–13020 (2008).
Takamatsu, H. et al. Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nature Immunol. 11, 594–600 (2010).
Kang, H. R., Lee, C. G., Homer, R. J. & Elias, J. A. Semaphorin 7A plays a critical role in TGF-β1-induced pulmonary fibrosis. J. Exp. Med. 204, 1083–1093 (2007).
Gan, Y. et al. Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum. 63, 2484–2494 (2011).
De Minicis, S. et al. Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis. Am. J. Pathol. 183, 820–830 (2013).
Kang, S. et al. Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via αvβ1 integrin. J. Immunol. 188, 1108–1116 (2012).
Czopik, A. K., Bynoe, M. S., Palm, N., Raine, C. S. & Medzhitov, R. Semaphorin 7A is a negative regulator of T cell responses. Immunity 24, 591–600 (2006).
Catalano, A. et al. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107, 3321–3329 (2006).
Catalano, A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J. Immunol. 185, 6373–6383 (2010).
Wen, H., Lei, Y., Eun, S.-Y. & Ting, J. P. Plexin-A4-semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. J. Exp. Med. 207, 2943–2957 (2010).
Wanschel, A. et al. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 33, 886–893 (2013).
Shimizu, I. et al. Semaphorin 3E-induced inflammation contributes to insulin resistance in dietary obesity. Cell. Metab. 18, 491–504 (2013).
Del Fattore, A., Teti, A. & Rucci, N. Bone cells and the mechanisms of bone remodelling. Front. Biosci. (Elite Ed.) 4, 2302–2321 (2012).
Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69–74 (2012).
Kular, J., Tickner, J., Chim, S. M. & Xu, J. An overview of the regulation of bone remodelling at the cellular level. Clin. Biochem. 45, 863–873 (2012).
Fukuda, T. et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature 497, 490–493 (2013).
Dacquin, R. et al. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS ONE 6, http://dx.doi.org/10.1371/journal.pone.0026627 (2011).
Fukushima, Y. et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J. Clin. Invest. 121, 1974–1985 (2011).
Moriya, J. et al. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis. Circ. Res. 106, 391–398 (2010).
Geretti, E., Shimizu, A. & Klagsbrun, M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11, 31–39 (2008).
Rivera, J. C. et al. Microglia and interleukin-1β in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler. Thromb. Vasc. Biol. 33, 1881–1891 (2013).
Fawcett, J. W., Schwab, M. E., Montani, L., Brazda, N. & Muller, H. W. Defeating inhibition of regeneration by scar and myelin components. Handb Clin. Neurol. 109, 503–522 (2012).
Pasterkamp, R. J. & Verhaagen, J. Semaphorins in axon regeneration: developmental guidance molecules gone wrong? Phil. Trans. R. Soc. 361, 1499–1511 (2006).
Okano, H. et al. Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient. World Patent WO2012115182 (A1) (2012).
Kikuchi, K. et al. In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin. J. Biol. Chem. 278, 42985–42991 (2003).
Masubuchi, M., Okuda, T. & Shimada, T. Antifungal agent, its preparation and microorganism therefor. European Patent EP0537622 (A1) (1993).
Gammon, G. et al. A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules. Eur. J. Immunol. 24, 991–998 (1994).
Kaneko, S. et al. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nature Med. 12, 1380–1389 (2006).
Omoto, M. et al. The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model. PLoS ONE 7, e47716 (2012).
Maeda, M. et al. Preparation for treatment of spinal cord injury. European Patent EP2601948(A1) (2011).
Montolio, M. et al. A semaphorin 3A inhibitor blocks axonal chemorepulsion and enhances axon regeneration. Chem. Biol. 16, 691–701 (2009).
Shim, S. O. et al. PlexinA2 limits recovery from corticospinal axotomy by mediating oligodendrocyte-derived Sema6A growth inhibition. Mol. Cell. Neurosci. 50, 193–200 (2012).
Taniguchi, M. et al. Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 19, 519–530 (1997).
Behar, O., Golden, J. A., Mashimo, H., Schoen, F. J. & Fishman, M. C. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383, 525–528 (1996).
Bouvree, K. et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ. Res. 111, 437–445 (2012).
Falk, J. et al. Dual functional activity of semaphorin 3B is required for positioning the anterior commissure. Neuron 48, 63–75 (2005).
Feiner, L. et al. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development 128, 3061–3070 (2001).
Reidy, K. & Tufro, A. Semaphorins in kidney development and disease: modulators of ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk. Pediatr. Nephrol. 26, 1407–1412 (2011).
Katz, T. C. et al. Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. Dev. Cell 22, 639–650 (2012).
Degenhardt, K. et al. Semaphorin 3d signaling defects are associated with anomalous pulmonary venous connections. Nature Med. 19, 760–765 (2013).
Gu, C. et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 307, 265–268 (2005).
Pecho-Vrieseling, E., Sigrist, M., Yoshida, Y., Jessell, T. M. & Arber, S. Specificity of sensory-motor connections encoded by Sema3e-PlexinD1 recognition. Nature 459, 842–846 (2009).
Choi, Y. I. et al. PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla. Immunity 29, 888–898 (2008).
Holl, E. K. et al. Plexin-D1 is a novel regulator of germinal centers and humoral immune responses. J. Immunol. 186, 5603–5611 (2011).
Sahay, A., Molliver, M. E., Ginty, D. D. & Kolodkin, A. L. Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. J. Neurosci. 23, 6671–6680 (2003).
Ito, K. et al. Semaphorin 3F confines ventral tangential migration of lateral olfactory tract neurons onto the telencephalon surface. J. Neurosci. 28, 4414–4422 (2008).
Tran, T. S. et al. Secreted semaphorins control spine distribution and morphogenesis in the postnatal CNS. Nature 462, 1065–1069 (2009).
Kutschera, S. et al. Differential endothelial transcriptomics identifies semaphorin 3G as a vascular class 3 semaphorin. Arterioscler. Thromb. Vasc. Biol. 31, 151–159 (2011).
Toyofuku, T. et al. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J. 26, 1373–1384 (2007).
Nakagawa, Y. et al. Identification of semaphorin 4B as a negative regulator of basophil-mediated immune responses. J. Immunol. 186, 2881–2888 (2011).
Maier, V. et al. Semaphorin 4C and 4G are ligands of Plexin-B2 required in cerebellar development. Mol. Cell. Neurosci. 46, 419–431 (2011).
Shi, W. et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 13, 633–642 (2000).
Witherden, D. A. et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. Immunity 37, 314–325 (2012).
Zhu, L. et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl Acad. Sci. USA 104, 1621–1626 (2007).
Fiore, R., Rahim, B., Christoffels, V. M., Moorman, A. F. & Puschel, A. W. Inactivation of the Sema5a gene results in embryonic lethality and defective remodeling of the cranial vascular system. Mol. Cell. Biol. 25, 2310–2319 (2005).
Matsuoka, R. L. et al. Class 5 transmembrane semaphorins control selective mammalian retinal lamination and function. Neuron 71, 460–473 (2011).
Renaud, J. et al. Plexin-A2 and its ligand, Sema6A, control nucleus-centrosome coupling in migrating granule cells. Nature Neurosci. 11, 440–449 (2008).
Bernard, F. et al. Role of transmembrane semaphorin Sema6A in oligodendrocyte differentiation and myelination. Glia 60, 1590–1604 (2012).
Kerjan, G. et al. The transmembrane semaphorin Sema6A controls cerebellar granule cell migration. Nature Neurosci. 8, 1516–1524 (2005).
Tawarayama, H., Yoshida, Y., Suto, F., Mitchell, K. J. & Fujisawa, H. Roles of semaphorin-6B and plexin-A2 in lamina-restricted projection of hippocampal mossy fibers. J. Neurosci. 30, 7049–7060 (2010).
Kuwajima, T. et al. Optic chiasm presentation of Semaphorin6D in the context of Plexin-A1 and Nr-CAM promotes retinal axon midline crossing. Neuron 74, 676–690 (2012).
Morote-Garcia, J. C., Napiwotzky, D., Kohler, D. & Rosenberger, P. Endothelial Semaphorin 7A promotes neutrophil migration during hypoxia. Proc. Natl Acad. Sci. USA 109, 14146–14151 (2012).
Yoshida, Y., Han, B., Mendelsohn, M. & Jessell, T. M. PlexinA1 signaling directs the segregation of proprioceptive sensory axons in the developing spinal cord. Neuron 52, 775–788 (2006).
Suto, F. et al. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. Neuron 53, 535–547 (2007).
Toyofuku, T. et al. Repulsive and attractive semaphorins cooperate to direct the navigation of cardiac neural crest cells. Dev. Biol. 321, 251–262 (2008).
Cheng, H. J. et al. Plexin-A3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections. Neuron 32, 249–263 (2001).
Yaron, A., Huang, P. H., Cheng, H. J. & Tessier-Lavigne, M. Differential requirement for Plexin-A3 and -A4 in mediating responses of sensory and sympathetic neurons to distinct class 3 Semaphorins. Neuron 45, 513–523 (2005).
Suto, F. et al. Plexin-a4 mediates axon-repulsive activities of both secreted and transmembrane semaphorins and plays roles in nerve fiber guidance. J. Neurosci. 25, 3628–3637 (2005).
Yamamoto, M. et al. Plexin-A4 negatively regulates T lymphocyte responses. Int. Immunol. 20, 413–420 (2008).
Deng, S. et al. Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and patterning of the developing nervous system in vivo. J. Neurosci. 27, 6333–6347 (2007).
Giacobini, P. et al. Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex. J. Cell Biol. 183, 555–566 (2008).
Friedel, R. H. et al. Plexin-B2 controls the development of cerebellar granule cells. J. Neurosci. 27, 3921–3932 (2007).
Perala, N. et al. Sema4C-Plexin B2 signalling modulates ureteric branching in developing kidney. Differentiation 81, 81–91 (2011).
Hirschberg, A. et al. Gene deletion mutants reveal a role for semaphorin receptors of the plexin-B family in mechanisms underlying corticogenesis. Mol. Cell. Biol. 30, 764–780 (2010).
Saha, B., Ypsilanti, A. R., Boutin, C., Cremer, H. & Chedotal, A. Plexin-B2 regulates the proliferation and migration of neuroblasts in the postnatal and adult subventricular zone. J. Neurosci. 32, 16892–16905 (2012).
Worzfeld, T. et al. Mice lacking Plexin-B3 display normal CNS morphology and behaviour. Mol. Cell. Neurosci. 42, 372–381 (2009).
Xu, C. & Fan, C. M. Allocation of paraventricular and supraoptic neurons requires Sim1 function: a role for a Sim1 downstream gene PlexinC1. Mol. Endocrinol. 21, 1234–1245 (2007).
Gitler, A. D., Lu, M. M. & Epstein, J. A. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev. Cell 7, 107–116 (2004).
Zhang, Y. et al. Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. Dev. Biol. 325, 82–93 (2009).
Zhu, L. et al. Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29, 1039–1045 (2009).
Yukawa, K. et al. Deletion of Sema4D gene reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Int. J. Mol. Med. 26, 39–44 (2010).
Li, M. et al. CD100 enhances dendritic cell and CD4+ cell activation leading to pathogenetic humoral responses and immune complex glomerulonephritis. J. Immunol. 177, 3406–3412 (2006).
Li, M. et al. Endogenous CD100 promotes glomerular injury and macrophage recruitment in experimental crescentic glomerulonephritis. Immunology 128, 114–122 (2009).
Shanks, K. et al. Neuroimmune semaphorin 4D is necessary for optimal lung allergic inflammation. Mol. Immunol. 56, 480–487 (2013).
Kigel, B., Rabinowicz, N., Varshavsky, A., Kessler, O. & Neufeld, G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood 118, 4285–4296 (2011).
Garcia-Areas, R. et al. Semaphorin 7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice. Front. Physiol. 5, 17 (2014).
Sultana, H. et al. Semaphorin 7A contributes to West Nile virus pathogenesis through TGF-β1/ Smad6 signaling. J. Immunol. 189, 3150–3158 (2012).
Hayashi, M. et al. Intrathecally administered Sema3A protein attenuates neuropathic pain behavior in rats with chronic constriction injury of the sciatic nerve. Neurosci. Res. 69, 17–24 (2011).
Vadivel, A. et al. The axonal guidance cue semaphorin 3C contributes to alveolar growth and repair. PLoS ONE 8, e67225 (2013).
Rogalewski, A. et al. Semaphorin 6A improves functional recovery in conjunction with motor training after cerebral ischemia. PLoS ONE 5, e10737 (2010).
Namavari, A. et al. Semaphorin 7a links nerve regeneration and inflammation in the cornea. Invest. Ophthalmol. Vis. Sci. 53, 4575–4585 (2012).
T.W. and S.O. hold a patent on B-type plexin antagonists and uses thereof.
Process by which new blood vessels form from pre-existing vessels.
Type of protein architecture characterized by several blade-shaped sheets that each typically consist of four antiparallel β-strands.
- GTPase-activating protein
(GAPs). Protein that binds to activated GTP-bound guanine nucleotide-binding proteins and stimulates their GTPase activity, thereby, in most cases, terminating signalling activity.
- PDZ domain
Protein domain of 80–90 amino acids that binds to a short region of the carboxyl terminus of other proteins.
- Guanine nucleotide exchange factors
(GEFs). Group of proteins that bind to guanine nucleotide-binding proteins and stimulate the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP), usually leading to activation of signalling.
- Epithelial–mesenchymal transition
(EMT). Process by which epithelial cells acquire migratory and invasive properties and increase their metastatic potential.
- Experimental autoimmune encephalomyelitis
(EAE). Animal model resembling the human disease multiple sclerosis.
Resident macrophages of the central nervous system.
- Atopic dermatitis
Relapsing skin disorder, often caused by allergic reactions.
Bone disorder characterized by decreased bone mass and density.
- Vitreous humour
Gel that fills the space between the retina and the lens of the eyeball.
Type of glial cell which forms a myelin sheath and thereby provides support and insulation to the long projections (axons) of nerve cells.
Surgical procedure by which the corticospinal tract — which conducts impulses from the brain to the spinal cord and thereby allows the execution of precise voluntary movements — is severed.
About this article
Cite this article
Worzfeld, T., Offermanns, S. Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov 13, 603–621 (2014). https://doi.org/10.1038/nrd4337
International Journal of Molecular Sciences (2020)
EMBO Molecular Medicine (2020)
Pharmacological Research (2020)
A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches
Biophysical Reviews (2020)
Characterization of Class-3 Semaphorin Receptors, Neuropilins and Plexins, as Therapeutic Targets in a Pan-Cancer Study